For uterine endometrial cancer, the combination of lenvatinib, which helps reduce tumor-associated macrophages (TAMs) and activate CD8+ T cells and pembrolizumab increased the prognosis [40, 41], potentially overcoming VEGF-mediated immunosuppression. The gene discussed is CD8A; the disease is neoplasm.